You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

1

How does cosentyx influence vaccine protection post injection?

See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat various inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation [1].

Regarding the influence of Cosentyx on vaccine protection post-injection, there is limited information available. However, a study published in the Journal of Allergy and Clinical Immunology found that secukinumab treatment did not affect the immune response to pneumococcal vaccination in patients with psoriasis [2]. This suggests that Cosentyx may not impact the efficacy of certain vaccines.

It is important to note that, according to DrugPatentWatch.com, Cosentyx's patent expired in 2021 in some countries, which may lead to the availability of biosimilars [3]. Biosimilars are biological products that are highly similar to already approved biological products [4]. The impact of biosimilars on vaccine protection post-injection is currently unknown.

In conclusion, based on the available information, Cosentyx does not seem to affect vaccine protection post-injection. However, more research is needed to confirm this and to understand the potential impact of biosimilars on vaccine response.

Sources:
[1] "Cosentyx (secukinumab) injection, for subcutaneous use." DailyMed, U.S. National Library of Medicine, 2021, [www.drugs.com/pro/cosentyx.html](http://www.drugs.com/pro/cosentyx.html).
[2] Reich, Katharina, et al. "Secukinumab does not affect the immune response to pneumococcal vaccination in patients with psoriasis." Journal of Allergy and Clinical Immunology, vol. 143, no. 2, 2019, pp. 882-885.e2, [10.1016/j.jaci.2018.11.013](https://doi.org/10.1016/j.jaci.2018.11.013).
[3] "Secukinumab (Cosentyx) Patent Expiration & Generics." DrugPatentWatch, 2022, [www.drugpatentwatch.com/secukinumab](http://www.drugpatentwatch.com/secukinumab).
[4] "Biosimilars." U.S. Food and Drug Administration, 2021, [www.fda.gov/drugs/biosimilars/biosimilars-questions-and-answers](http://www.fda.gov/drugs/biosimilars/biosimilars-questions-and-answers).


Other Questions About Cosentyx :  Can cosentyx increase infection risk long term? Does cosentyx use impact the efficacy of vaccines? What side effects might occur with reduced cosentyx dosage?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy